Here's your US review and approval news in brief: For the first time in a decade, a drugmaker has scored an approval for an HIV treatment with a new mechanism of action, with TaiMed Biologics Inc. winning the US FDA's blessing for the CD4-directed post-attachment HIV-1 inhibitor Trogarzo (ibalizumab-uiyk).
Bristol-Myers Squibb Co.landed a newly approved dosing regimen for Opdivo (nivolumab), as the drugmaker seeks to separate its PD-1...








